Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disea...

od Bruera, Gemma, Ricevuto, Enrico
izdano v Front Oncol (2020)

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

od Bruera, Gemma, Ricevuto, Enrico
izdano v Pharmgenomics Pers Med (2020)

Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy

od Bruera, Gemma, Russo, Antonio, Galvano, Antonio, Rizzo, Sergio, Ricevuto, Enrico
izdano v Oncotarget (2016)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

od Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Vicentini, Roberto, Ficorella, Corrado, Ricevuto, Enrico
Izdano 2013

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment...

od BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Izdano 2013

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen

od BRUERA, GEMMA, CANNITA, KATIA, GIORDANO, ALDO VICTOR, VICENTINI, ROBERTO, FICORELLA, CORRADO, RICEVUTO, ENRICO
Izdano 2014

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemothe...

od Bruera, Gemma, D'Andrilli, Antonio, Simmaco, Maurizio, Guadagni, Stefano, Rendina, Erino Angelo, Ricevuto, Enrico
izdano v Front Oncol (2020)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer

od Bruera, Gemma, Massacese, Silvia, Galvano, Antonio, Mas, Antonella Dal, Guadagni, Stefano, Calvisi, Giuseppe, Ciacco, Eugenio, Russo, Antonio, Ricevuto, Enrico
izdano v Oncotarget (2018)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-...

od Bruera, Gemma, Pepe, Francesco, Malapelle, Umberto, Pisapia, Pasquale, Mas, Antonella Dal, Di Giacomo, Daniela, Calvisi, Giuseppe, Troncone, Giancarlo, Ricevuto, Enrico
izdano v Oncotarget (2018)

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction...

od Bruera, Gemma, Massacese, Silvia, Pepe, Francesco, Malapelle, Umberto, Dal Mas, Antonella, Ciacco, Eugenio, Calvisi, Giuseppe, Troncone, Giancarlo, Simmaco, Maurizio, Ricevuto, Enrico
izdano v Ther Adv Med Oncol (2019)

Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line...

od Bruera, Gemma, Giuliani, Antonio, Romano, Lucia, Chiominto, Alessandro, Di Sibio, Alessandra, Mastropietro, Stefania, Cosenza, Pierluigi, Ricevuto, Enrico, Schietroma, Mario, Carlei, Francesco
izdano v BMC Cancer (2019)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

od Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Frébourg, Thierry, Sabourin, Jean Christophe, Tosi, Mario, Alesse, Edoardo, Ficorella, Corrado, Ricevuto, Enrico
Izdano 2013

Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

od Bruera, Gemma, Cannita, Katia, Giordano, Aldo Victor, Manetta, Rosa, Vicentini, Roberto, Carducci, Sergio, Saltarelli, Patrizia, Iapadre, Nerio, Coletti, Gino, Ficorella, Corrado, Ricevuto, Enrico
Izdano 2014

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II st...

od Bruera, Gemma, Santomaggio, Alessandra, Cannita, Katia, Baldi, Paola Lanfiuti, Tudini, Marianna, De Galitiis, Federica, Mancini, Maria, Marchetti, Paolo, Antonucci, Adelmo, Ficorella, Corrado, Ricevuto, Enrico
Izdano 2010

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

od Bruera, Gemma, Massacese, Silvia, Candria, Stefania, Galvano, Antonio, Manetta, Rosa, Giordano, Aldo Victor, Carducci, Sergio, Di Sibio, Alessandra, Ciacco, Eugenio, Russo, Antonio, Ricevuto, Enrico
izdano v Oncotarget (2018)

Dose-Dense Nonpegylated Liposomal Doxorubicin and Docetaxel Combination in Breast Cancer: Dose-Finding Study

od Ricevuto, Enrico, Cocciolone, Valentina, Mancini, Maria, Cannita, Katia, Romano, Silvio, Bruera, Gemma, Pelliccione, Michela, Adinolfi, Maria Ilaria, Ciccozzi, Antonietta, Bafile, Alberto, Penco, Maria, Ficorella, Corrado
izdano v Oncologist (2015)

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy...

od Guadagni, Stefano, Fiorentini, Giammaria, Mambrini, Andrea, Masedu, Francesco, Valenti, Marco, Mackay, Andrew Reay, Sarti, Donatella, Ricevuto, Enrico, Clementi, Marco, Catarci, Marco, Lazzarin, Gianni, Bruera, Gemma
izdano v Oncotarget (2019)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer

od Bruera, Gemma, Di Staso, Mario, Bonfili, Pierluigi, Galvano, Antonio, Manetta, Rosa, Coletti, Gino, Vicentini, Roberto, Guadagni, Stefano, Ficorella, Corrado, Di Cesare, Ernesto, Russo, Antonio, Ricevuto, Enrico
izdano v Oncotarget (2018)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of...

od Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, Lamy, Aude, Troncone, Giancarlo, Dal Mas, Antonella, Coletti, Gino, Frébourg, Thierry, Sabourin, Jean Christophe, Tosi, Mario, Ficorella, Corrado, Ricevuto, Enrico
Izdano 2012

Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study

od Guadagni, Stefano, Fiorentini, Giammaria, De Simone, Michele, Masedu, Francesco, Zoras, Odisseas, Mackay, Andrew Reay, Sarti, Donatella, Papasotiriou, Ioannis, Apostolou, Panagiotis, Catarci, Marco, Clementi, Marco, Ricevuto, Enrico, Bruera, Gemma
izdano v J Cancer Res Clin Oncol (2019)